A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

Phase 2 Completed 420 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the efficacy and safety of an MK 0974 for migraine headache and to identify an appropriate dose range for further study.

Timeline

Start: 2005-11
Primary completion: 2006-05
Completion: 2006-05

Publications

Background Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM; MK-0974 Protocol 004 study group. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008 Apr 15;70(16):1304-12. doi: 10.1212/01.WNL.0000286940.29755.61. Epub 2007 Oct 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Telcagepant	Small molecule	25 mg	Oral
Subject	Telcagepant	Small molecule	50 mg	Oral
Subject	Telcagepant	Small molecule	100 mg	Oral
Subject	Telcagepant	Small molecule	200 mg	Oral
Subject	Telcagepant	Small molecule	300 mg	Oral
Subject	Telcagepant	Small molecule	400 mg	Oral
Subject	Telcagepant	Small molecule	600 mg	Oral
Comparator	rizatriptan	Unknown	10 mg	Oral

A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

Summary

Timeline

Publications

Drugs

Indications